GLS and nonpapillary renal cell carcinoma: Glutaminase inhibitors have been used in preclinical studies to inhibit glutamine-derived pyrimidine biosynthesis in ccRCC cells resulting in DNA replication stress and growth arrest that could be further leveraged with PARPis (15).